4 stories mentioning KRX:326030Updated 1d ago
Every FINWIRES story that references KRX:326030, newest first.
SK Biopharmaceuticals (KRX:326030) posted a 158% year-over-year jump in net income attributable to owners of the parent to 85.1 billion won from 32.9 billion won for the second quarter.Sales rose 40% to 247.4 billion won from 176.3 billion won for the three months ended June 30.Shares of the pharmaceutical company rose 5% in recent trade.
Insilico Medicine (HKG:3696) and SK Biopharmaceuticals (KRX:326030) have signed a drug discovery collaboration deal focused on neuroimmune disorders of the central nervous system, with a total potential value exceeding $2.5 billion, according to a Monday Hong Kong bourse filing.Under the agreement, Insilico will use its artificial intelligence-powered Pharma.AI platform and drug discovery capabilities to identify and optimize drug candidates. Whereas, SK Biopharmaceuticals will lead late-stage development and commercialization, the filing said.Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential value of the deal exceeds $2.5 billion, including development, regulatory, and commercial milestones, as well as single-digit royalties on future product sales.The collaboration focuses on neuroimmune diseases and expands Insilico's use of AI-driven drug discovery technologies in central nervous system disorders.
South Korean stocks closed at a fresh high on Thursday as investor sentiment was buoyed by optimism regarding a potential US-Iran peace agreement.The Korea Composite Stock Price Index or Kospi increased by 105.49 points, or 1.4%, to end at 7,490.05. The Kosdaq slipped 0.9% to close at 1,199.18.The key index was lifted by gains in market heavyweights Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660), which rose more than 2% and 3%, respectively.In economic news, South Korea's foreign reserves grew to $427.9 billion in April from $423.7 billion as of March-end, data from the Bank of Korea showed.In corporate news, SK Biopharmaceuticals (KRX:326030) finished 1% higher after posting a first-quarter attributable income of 105.2 billion won, up 351% from 23.3 billion won a year earlier.
SK Biopharmaceuticals (KRX:326030) posted first-quarter net income attributable to shareholders of 105.2 billion won, up 351% from 23.3 billion won a year earlier, according to a Thursday filing with the Korea Exchange.The South Korean biopharmaceutical firm's sales rose 58% year over year to 227.9 billion won from 144.4 billion won.Shares of SK Biopharmaceuticals rose more than 2% in recent trade.
